{"disease":{"id":"cerebral-edema","name":"Cerebral edema","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":15,"pipeline_drug_count":0,"trial_count":1},"drugs":{"marketed":[{"drug_id":"dexamethasone-phosphate","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dexamethasone Sodium Phosphate","generic_name":"dexamethasone phosphate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Androgen receptor, Glucocorticoid receptor, Mineralocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-succinate","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone-acetate","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Solitaire FR Revascularization Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema in the Posterior Circulation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with a Large Vessel Occlusion and Malignant Cerebral Edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Trevo Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Stentriever Device and a Penumbra System","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Solitaire FR Revascularization Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"best-available-treatment","indication_name":"Acute Ischemic Stroke with Malignant Cerebral Edema in the Posterior Circulation and a Baseline NIH Stroke Scale Score of 10 or Greater and a Time to Treatment of 4.5 to 6 Hours and a Mechanical Thrombectomy Device and a Stentriever Device and a Trevo Device","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Best Available Treatment","generic_name":"best-available-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":52,"revenue":null,"mechanism":"Not specified on Wikipedia"},{"drug_id":"cortisone-acetate","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"mannitol-20","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mannitol","generic_name":"Mannitol","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Glomerular filtrate osmolarity; intracellular water movement","drug_class":"Osmotic diuretic","quality_score":66,"revenue":null,"mechanism":"Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption."},{"drug_id":"methylprednisolone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"mannitol","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aridol Kit","generic_name":"MANNITOL","company_name":"Baxter","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"Osmotic Diuretic [EPC]","quality_score":75,"revenue":null,"mechanism":"Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body."},{"drug_id":"betamethasone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"cortisol","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"prednisolon","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolon","indication_name":"Cerebral edema","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":59,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06290076","title":"A Predictive Model and Scoring System for Severe Complications After Endovascular Thrombectomy","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT03243539","title":"Implementation of Neuro Lung Protective Ventilation","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":728,"lead_sponsor_name":"Colin Grissom","has_results":false},{"nct_id":"NCT04303065","title":"Trial of Dexamethasone for Traumatic Brain Injured Patients With Brain Contusions and Pericontusional Edema","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":600,"lead_sponsor_name":"Jon Pérez Bárcena","has_results":false},{"nct_id":"NCT07118345","title":"Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial","phase":"NA","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Xuanwu Hospital, Beijing","has_results":false},{"nct_id":"NCT07195786","title":"Expansion-floating Craniotomy for the Treatment of Malignant Cerebral Edema Caused by Acute Ischemic Stroke","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":356,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT07422636","title":"Wet and Dry Biomarkers to Predict Secondary Injury in Stroke: From Bench to Bedside - The NIMBLE Study","phase":"","overall_status":"COMPLETED","enrollment_count":213,"lead_sponsor_name":"University of Florence","has_results":false},{"nct_id":"NCT05725694","title":"Acute Ischaemic STROKE: From LAboratory to the Patient's BED","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Istituto di Neuroscienze Consiglio Nazionale delle Ricerche","has_results":false},{"nct_id":"NCT04247659","title":"Study on the Relationship Between Asymmetric Vascular Sign of Cortex and Prognosis in Massive Cerebral Infarction","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"The Second Hospital of Hebei Medical University","has_results":false},{"nct_id":"NCT06039475","title":"Risk Factors Associated With High Altitude Sickness: A Case-Control Study","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"B.P. Koirala Institute of Health Sciences","has_results":false},{"nct_id":"NCT05585255","title":"Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury","phase":"","overall_status":"UNKNOWN","enrollment_count":108,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT03273179","title":"Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Capital Medical University","has_results":false},{"nct_id":"NCT06009016","title":"Inflammation and Coagulation Factors for Predicting Cerebral Edema After SAH","phase":"","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT05200728","title":"The Tolerability, Safety, and PK Characteristics of SIM1910-09 in Healthy Chinese Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Jiangsu Simcere Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06515145","title":"High-volume Versus Standard Volume Plasma Exchange in Patients With Acute Liver Failure With Cerebral Edema","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Institute of Liver and Biliary Sciences, India","has_results":false},{"nct_id":"NCT06018545","title":"AI Assisted Reader Evaluation in Acute Computed Tomography (CT) Head Interpretation","phase":"","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT04088630","title":"Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT04414020","title":"Cytoprotective Effect and Clinical Outcome of Perioperative Proesterone in Brain Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Minia University","has_results":false},{"nct_id":"NCT05060159","title":"Conventional Hemodialysis Versus Post-Dilution Hemofiltration in Incident RRT","phase":"NA","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Instituto Nacional de Cardiologia Ignacio Chavez","has_results":false},{"nct_id":"NCT05796349","title":"Study on Data Acquisition and Image Characteristics of Brain Multifrequency EIT in Healthy People and Patients With Brain Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Jieshi Ma","has_results":false},{"nct_id":"NCT05170295","title":"Noninvasive Monitoring of Cerebral Blood Flow Autoregulation","phase":"","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Ochsner Health System","has_results":false},{"nct_id":"NCT07386262","title":"A Trial of Adacolumn on Cerebral Edema After Anterior Circulation Ischemic Stroke","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03341676","title":"Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"University Hospitals Coventry and Warwickshire NHS Trust","has_results":false},{"nct_id":"NCT04116138","title":"Antisecretory Factor in Primary Glioblastoma 1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Peter Siesjö","has_results":false},{"nct_id":"NCT03000283","title":"Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Jesse Corry","has_results":true},{"nct_id":"NCT03276494","title":"Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Ohio State University","has_results":true},{"nct_id":"NCT02460874","title":"Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":true},{"nct_id":"NCT03330704","title":"Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation","phase":"EARLY_PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Stanford University","has_results":false},{"nct_id":"NCT03409237","title":"Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Neuromed IRCCS","has_results":false}],"total":28},"guidelines":[{"drug_id":"mannitol-25","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the treatment of cerebral edema.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"mannitol-5","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the treatment of cerebral edema.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null},{"drug_id":"mannitol-10","guideline_body":"FDA label","recommendation":"OSMITROL is indicated for the treatment of cerebral edema.","line_of_therapy":"1L","evidence_grade":"B","guideline_year":null}],"source":"Drug Landscape verified database"}